INDV
Indivior Pharmaceuticals IncHealthcare · $4.5B market cap
Verdict
Share price
$35.71
close of Oct 3, 2026
Fair value
$28.19
Sticker Price
Payback Price
$11.28
buy price
INDV is Overpriced: at $35.71 it trades 27% above its fair value of $28.19. Its buy price (Payback Price) is $11.28, 68% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.
How we valued it
Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow INDV
Get notified when it reaches its buy price of $11.28. Free.
Create a free accountSuperinvestors
1 of the investors we track holds INDV. In Q2 2026, 1 trimmed. Who we track
Moves in Q2 2026
Trimmed: Howard Marks
Insider activity
Since Jun 22, 2026: 2 open-market purchases worth $108K, 1 sale worth $765K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Purchases
Anderson Woodrow D
Chief Accounting Officer · 2026-08-27
Bought
$54K
Anderson Woodrow D
Chief Accounting Officer · 2026-08-05
Bought
$54K
Sales
Other filings
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works